|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cohen R and Platell CF: Metachronous
colorectal cancer metastasis: Who, what, when and what to do about
it. J Surg Oncol. 129:71–77. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hansdotter P, Scherman P, Nikberg M,
Petersen SH, Holmberg E, Rizell M, Naredi P and Syk I; COLOFOL
study group, : Treatment and survival of patients with metachronous
colorectal lung metastases. J Surg Oncol. 127:806–814. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reboux N, Jooste V, Goungounga J,
Robaszkiewicz M, Nousbaum JB and Bouvier AM: Incidence and survival
in synchronous and metachronous liver metastases from colorectal
cancer. JAMA Netw Open. 5:e22366662022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Martin J, Petrillo A, Smyth EC, Shaida N,
Khwaja S, Cheow HK, Duckworth A, Heister P, Praseedom R, Jah A, et
al: Colorectal liver metastases: Current management and future
perspectives. World J Clin Oncol. 11:761–808. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pfannschmidt J, Dienemann H and Hoffmann
H: Surgical resection of pulmonary metastases from colorectal
cancer: A systematic review of published series. Ann Thorac Surg.
84:324–338. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Biller LH and Schrag D: Diagnosis and
treatment of metastatic colorectal cancer: A review. JAMA.
325:669–685. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Boutin AT, Liao WT, Wang M, Hwang SS,
Karpinets TV, Cheung H, Chu GC, Jiang S, Hu J, Chang K, et al:
Oncogenic Kras drives invasion and maintains metastases in
colorectal cancer. Genes Dev. 31:370–382. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lemieux E, Cagnol S, Beaudry K, Carrier J
and Rivard N: Oncogenic KRAS signalling promotes the Wnt/β-catenin
pathway through LRP6 in colorectal cancer. Oncogene. 34:4914–4927.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Feng Q, Liang L, Ren L, Chen J, Wei Y,
Chang W, Zhu D, Lin Q, Zheng P and Xu J: A specific KRAS codon 13
mutation is an independent predictor for colorectal cancer
metachronous distant metastases. Am J Cancer Res. 5:674–688.
2015.PubMed/NCBI
|
|
11
|
Ilm K, Kemmner W, Osterland M, Burock S,
Koch G, Herrmann P, Schlag PM and Stein U: High MACC1 expression in
combination with mutated KRAS G13 indicates poor survival of
colorectal cancer patients. Mol Cancer. 14:382015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hao M, Li H, Wang K, Liu Y, Liang X and
Ding L: Predicting metachronous liver metastasis in patients with
colorectal cancer: Development and assessment of a new nomogram.
World J Surg Oncol. 20:802022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Herzberg BO and Manji GA: KRAS: druggable
at last. Oncologist. 28:283–286. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Abubaker J, Bavi P, Al-Haqawi W, Sultana
M, Al-Harbi S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S,
Al-Dayel F, et al: Prognostic significance of alterations in KRAS
isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J
Pathol. 219:435–445. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nusrat M and Yaeger R: KRAS inhibition in
metastatic colorectal cancer: An update. Curr Opin Pharmacol.
68:1023432023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim D, Herdeis L, Rudolph D, Zhao Y,
Böttcher J, Vides A, Ayala-Santos CI, Pourfarjam Y, Cuevas-Navarro
A, Xue JY, et al: Pan-KRAS inhibitor disables oncogenic signalling
and tumour growth. Nature. 619:160–166. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ji Q, Liu X, Han Z, Zhou L, Sui H, Yan L,
Jiang H, Ren J, Cai J and Li Q: Resveratrol suppresses
epithelial-to-mesenchymal transition in colorectal cancer through
TGF-β1/Smads signaling pathway mediated Snail/E-cadherin
expression. BMC Cancer. 15:972015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moher D, Liberati A, Tetzlaff J and Altman
DG; Group P, : Preferred reporting items for systematic reviews and
meta-analyses: The PRISMA statement. PLoS Med. 6:e10000972009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chatila WK, Kim JK, Walch H, Marco MR,
Chen CT, Wu F, Omer DM, Khalil DN, Ganesh K, Qu X, et al: Genomic
and transcriptomic determinants of response to neoadjuvant therapy
in rectal cancer. Nat Med. 28:1646–1655. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Roelands J, Kuppen PJK, Ahmed EI, Mall R,
Masoodi T, Singh P, Monaco G, Raynaud C, de Miranda NFCC, Ferraro
L, et al: An integrated tumor, immune and microbiome atlas of colon
cancer. Nat Med. 29:1273–1286. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Medico E, Russo M, Picco G, Cancelliere C,
Valtorta E, Corti G, Buscarino M, Isella C, Lamba S, Martinoglio B,
et al: The molecular landscape of colorectal cancer cell lines
unveils clinically actionable kinase targets. Nat Commun.
6:70022015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim WK, Kwon Y, Jang M, Park M, Kim J, Cho
S, Jang DG, Lee WB, Jung SH, Choi HJ, et al: β-catenin activation
down-regulates cell-cell junction-related genes and induces
epithelial-to-mesenchymal transition in colorectal cancers. Sci
Rep. 9:184402019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu Z, Deng P, Chen Y, Liu S, Chen J, Yang
Z, Chen J, Fan X, Wang P, Cai Z, et al: Inhibition of the
PLK1-coupled cell cycle machinery overcomes resistance to
oxaliplatin in colorectal cancer. Adv Sci (Weinh). 8:e21007592021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen S, Zhou Y, Chen Y and Gu J: fastp: An
ultra-fast all-in-one FASTQ preprocessor. Bioinformatics.
34:i884–i890. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dobin A, Davis CA, Schlesinger F, Drenkow
J, Zaleski C, Jha S, Batut P, Chaisson M and Gingeras TR: STAR:
Ultrafast universal RNA-seq aligner. Bioinformatics. 29:15–21.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li B and Dewey CN: RSEM: Accurate
transcript quantification from RNA-Seq data with or without a
reference genome. BMC Bioinformatics. 12:3232011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kanehisa M, Furumichi M, Sato Y, Matsuura
Y and Ishiguro-Watanabe M: KEGG: Biological systems database as a
model of the real world. Nucleic Acids Res. gkae9092024.(Epub ahead
of print). View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liberzon A, Birger C, Thorvaldsdóttir H,
Ghandi M, Mesirov JP and Tamayo P: The molecular signatures
database (MSigDB) hallmark gene set collection. Cell Syst.
1:417–425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Engstrand J, Stromberg C, Nilsson H,
Freedman J and Jonas E: Synchronous and metachronous liver
metastases in patients with colorectal cancer-towards a clinically
relevant definition. World J Surg Oncol. 17:2282019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kuan TC, Chang SC, Lin JK, Lin TC, Yang
SH, Jiang JK, Chen WS, Wang HS, Lan YT, Lin CC, et al:
Prognosticators of long-term outcomes of TNM stage II colorectal
cancer: Molecular patterns or clinicopathological features. World J
Surg. 43:3207–3215. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jo P, Bernhardt M, Nietert M, König A,
Azizian A, Schirmer MA, Grade M, Kitz J, Reuter-Jessen K, Ghadimi
M, et al: KRAS mutation status concordance between the primary
tumor and the corresponding metastasis in patients with rectal
cancer. PLoS One. 15:e02398062020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lin CC, Lin JK, Lin TC, Chen WS, Yang SH,
Wang HS, Lan YT, Jiang JK, Yang MH and Chang SC: The prognostic
role of microsatellite instability, codon-specific KRAS, and BRAF
mutations in colon cancer. J Surg Oncol. 110:451–457. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tsunoda A, Iijima T, Tsunoda Y, Nakao K,
Miyaki M and Kusano M: Association of K-ras mutations with liver
metastases from colorectal carcinoma. Anticancer Res. 24:2471–2476.
2004.PubMed/NCBI
|
|
35
|
Vakiani E, Shah RH, Berger MF,
Makohon-Moore AP, Reiter JG, Ostrovnaya I, Attiyeh MA, Cercek A,
Shia J, Iacobuzio-Donahue CA, et al: Local recurrences at the
anastomotic area are clonally related to the primary tumor in
sporadic colorectal carcinoma. Oncotarget. 8:42487–42494. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sperlich A, Balmert A, Doll D, Bauer S,
Franke F, Keller G, Wilhelm D, Mur A, Respondek M, Friess H, et al:
Genetic and immunological biomarkers predict metastatic disease
recurrence in stage III colon cancer. BMC Cancer. 18:9982018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nitsche U, Rosenberg R, Balmert A,
Schuster T, Slotta-Huspenina J, Herrmann P, Bader FG, Friess H,
Schlag PM, Stein U and Janssen KP: Integrative marker analysis
allows risk assessment for metastasis in stage II colon cancer. Ann
Surg. 256:763–771. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nakamura Y, Yokoyama S, Matsuda K, Tamura
K, Mitani Y, Iwamoto H, Mizumoto Y, Murakami D, Kitahata Y and
Yamaue H: Preoperative detection of KRAS mutated circulating tumor
DNA is an independent risk factor for recurrence in colorectal
cancer. Sci Rep. 11:4412021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Huang SC, Huang SF, Chen YT, Chang Y, Chiu
YT, Chang IC, Wu HI and Chen JS: Overexpression of MutL homolog 1
and MutS homolog 2 proteins have reversed prognostic implications
for stage I–II colon cancer patients. Biomed J. 40:39–48. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
El Otmani I, El Agy F, El Baradai S,
Bouguenouch L, Lahmidani N, El Abkari M, Benajah DA, Toughrai I, El
Bouhaddouti H, Mouaqit O, et al: Analysis of molecular pretreated
tumor profiles as predictive biomarkers of therapeutic response and
survival outcomes after neoadjuvant therapy for rectal cancer in
moroccan population. Dis Markers. 2020:84593032020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Birgisson H, Edlund K, Wallin U, Påhlman
L, Kultima HG, Mayrhofer M, Micke P, Isaksson A, Botling J,
Glimelius B and Sundström M: Microsatellite instability and
mutations in BRAF and KRAS are significant predictors of
disseminated disease in colon cancer. BMC Cancer. 15:1252015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Verhagen MP, Xu T, Stabile R, Joosten R,
Tucci FA, van Royen M, Trerotola M, Alberti S, Sacchetti A and
Fodde R: The SW480 cell line as a model of resident and migrating
colon cancer stem cells. iScience. 27:1106582024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dhillon S: Adagrasib: First approval.
Drugs. 83:275–285. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Awad MM, Liu S, Rybkin II, Arbour KC,
Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ, et al:
Acquired resistance to KRASG12C inhibition in cancer. N
Engl J Med. 384:2382–2393. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Flum M, Dicks S, Teng YH, Schrempp M,
Nyström A, Boerries M and Hecht A: Canonical TGFβ signaling induces
collective invasion in colorectal carcinogenesis through a Snail1-
and Zeb1-independent partial EMT. Oncogen. 41:1492–1506. 2022.
View Article : Google Scholar
|
|
46
|
Sánchez-Tilló E, Pedrosa L, Vila I, Chen
Y, Győrffy B, Sánchez-Moral L, Siles L, Lozano JJ, Esteve-Codina A,
Darling DS, et al: The EMT factor ZEB1 paradoxically inhibits EMT
in BRAF-mutant carcinomas. JCI Insight. 8:e1646292023. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lee JK, Sivakumar S, Schrock AB, Madison
R, Fabrizio D, Gjoerup O, Ross JS, Frampton GM, Napalkov P,
Montesion M, et al: Comprehensive pan-cancer genomic landscape of
KRAS altered cancers and real-world outcomes in solid tumors. NPJ
Precis Oncol. 6:912022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Huang D, Sun W, Zhou Y, Li P, Chen F, Chen
H, Xia D, Xu E, Lai M, Wu Y and Zhang H: Mutations of key driver
genes in colorectal cancer progression and metastasis. Cancer
Metastasis Rev. 37:173–187. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Meng M, Zhong K, Jiang T, Liu Z, Kwan HY
and Su T: The current understanding on the impact of KRAS on
colorectal cancer. Biomed Pharmacother. 140:1117172021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pereira AAL, Rego JFM, Morris V, Overman
MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang ZQ, et
al: Association between KRAS mutation and lung meta-stasis in
advanced colorectal cancer. Br J Cancer. 112:424–428. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tie J, Lipton L, Desai J, Gibbs P,
Jorissen RN, Christie M, Drummond KJ, Thomson BN, Usatoff V, Evans
PM, et al: KRAS mutation is associated with lung metastasis in
patients with curatively resected colorectal cancer. Clin Cancer
Res. 17:1122–1130. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Guo L, Wang Y, Yang W, Wang C, Guo T, Yang
J, Shao Z, Cai G, Cai S, Zhang L, et al: Molecular profiling
provides clinical insights into targeted and immunotherapies as
well as colorectal cancer prognosis. Gastroenterology.
165:414–428.e7. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Iseas S, Sendoya JM, Robbio J, Coraglio M,
Kujaruk M, Mikolaitis V, Rizzolo M, Cabanne A, Ruiz G, Salanova R,
et al: Prognostic impact of an integrative landscape of clinical,
immune, and molecular features in non-metastatic rectal cancer.
Front Oncol. 11:8018802022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Misale S, Di Nicolantonio F,
Sartore-Bianchi A, Siena S and Bardelli A: Resistance to anti-EGFR
therapy in colorectal cancer: From heterogeneity to convergent
evolution. Cancer Discov. 4:1269–1280. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lal N, White BS, Goussous G, Pickles O,
Mason MJ, Beggs AD, Taniere P, Willcox BE, Guinney J and Middleton
GW: KRAS mutation and consensus molecular subtypes 2 and 3 are
independently associated with reduced immune infiltration and
reactivity in colorectal cancer. Clin Cancer Res. 24:224–233. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Caughey BA and Strickler JH: Targeting
KRAS-mutated gastrointestinal malignancies with small-molecule
inhibitors: A new generation of breakthrough therapies. Drugs.
84:27–44. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Erlanson DA and Webster KR: Targeting
mutant KRAS. Curr Opin Chem Biol. 62:101–108. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hallin J, Engstrom LD, Hargis L, Calinisan
A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA,
et al: The KRASG12C Inhibitor MRTX849 provides insight
toward therapeutic susceptibility of KRAS-mutant cancers in mouse
models and patients. Cancer Discov. 10:54–71. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Popat S, Hubner R and Houlston RS:
Systematic review of microsatellite instability and colorectal
cancer prognosis. J Clin Oncol. 23:609–618. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Storojeva I, Boulay JL, Heinimann K,
Ballabeni P, Terracciano L, Laffer U, Mild G, Herrmann R and
Rochlitz C: Prognostic and predictive relevance of microsatellite
instability in colorectal cancer. Oncol Rep. 14:241–249.
2005.PubMed/NCBI
|
|
61
|
Berg KCG, Eide PW, Eilertsen IA,
Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA,
Eknæs M, Lind GE, et al: Multi-omics of 34 colorectal cancer cell
lines-a resource for biomedical studies. Mol Cancer. 16:1162017.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Vu T and Datta P: Regulation of EMT in
colorectal cancer: A culprit in metastasis. Cancers (Basel).
9:1712017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wang K, Song K, Ma Z, Yao Y, Liu C, Yang
J, Xiao H, Zhang J, Zhang Y and Zhao W: Identification of
EMT-related high-risk stage II colorectal cancer and
characterisation of metastasis-related genes. Br J Cancer.
123:410–417. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chu PC, Lin PC, Wu HY, Lin KT, Wu C,
Bekaii-Saab T, Lin YJ, Lee CT, Lee JC and Chen CS: Mutant KRAS
promotes liver metastasis of colorectal cancer, in part, by
upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling
pathway. Oncogene. 37:3440–3455. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Adachi Y, Kimura R, Hirade K, Yanase S,
Nishioka Y, Kasuga N, Yamaguchi R and Ebi H: Scribble
mis-localization induces adaptive resistance to KRAS G12C
inhibitors through feedback activation of MAPK signaling mediated
by YAP-induced MRAS. Nat Cancer. 4:829–843. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Vivekanandhan S and Mukhopadhyay D:
Genetic status of KRAS influences transforming growth factor-beta
(TGF-β) signaling: An insight into neuropilin-1 (NRP1) mediated
tumorigenesis. Semin Cancer Biol. 54:72–79. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Pohl M, Radacz Y, Pawlik N, Schoeneck A,
Baldus SE, Munding J, Schmiegel W, Schwarte-Waldhoff I and
Reinacher-Schick A: SMAD4 mediates mesenchymal-epithelial reversion
in SW480 colon carcinoma cells. Anticancer Res. 30:2603–2613.
2010.PubMed/NCBI
|
|
68
|
Lee J, Ballikaya S, Schönig K, Ball CR,
Glimm H, Kopitz J and Gebert J: Transforming growth factor beta
receptor 2 (TGFBR2) changes sialylation in the microsatellite
unstable (MSI) Colorectal cancer cell line HCT116. PLoS One.
8:e570742013. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Hawinkels LJAC, Paauwe M, Verspaget HW,
Wiercinska E, van der Zon JM, van der Ploeg K, Koelink PJ, Lindeman
JH, Mesker W, ten Dijke P and Sier CF: Interaction with colon
cancer cells hyperactivates TGF-β signaling in cancer-associated
fibroblasts. Oncogene. 33:97–107. 2014. View Article : Google Scholar : PubMed/NCBI
|
